A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Researcher Information

Arif Hussain, M.D.
Professor

Department:
Medicine, Biochemistry and Molecular Biology, Pathology

UMGCC Research Program:
Hormone Responsive Cancers Program

Education/Training:
College Degree: Howard University
Medical Degree: Howard University
Residency: Washington Hospital Center
Fellowship: University of Maryland Greenebaum Cancer Center, Hematology/Oncology
Certification: Medical Oncology, Internal Medicine

Contact Information:

Mailing Address: Bressler Research Building, 9-047
University of Maryland Greenebaum Cancer Center
Baltimore, MD 21201
Email: ahussain@som.umaryland.edu
Phone: 410-328-7225
Fax: 410-328-6559

Research Interests:
My area of clinical interest is in genito-urinary malignancies, including developing multi-modal therapies in patients with high risk prostate cancer and recurrent prostate cancer. In addition, our aim is to help identify and develop active treatment regimens for advanced, hormone resistant prostate cancer and advanced bladder cancer. Another area of active ongoing work is related to the problem of bone metastasis, which is a particularly relevant issue in advanced prostate cancer. We are developing and testing several novel treatment combinations for all the above disease states of prostate cancer. Currently I am the Principal Investigator of ten active clinical trials in prostate cancer and bladder cancer.

My laboratory research is directed in two areas: (1) We are using two pre-clinical mouse models of prostate cancer, including a xenograft model and a transgenic model (TRAMP) to study the antitumor effects of chemotherapy and hormone ablation, with the aim to determine optimal integration of these treatment modalities for therapeutic effect. These studies are being complimented with immunohistochemical analysis of various markers of apoptosis, angiogenesis and cell proliferation. (2) The second area of research is to study mechanisms of drug resistance and cell signaling in human prostate cancer cells that have been selected for resistance to agents that disrupt cellular calcium homeostasis and microtubular stability.

Our research program has been supported by clinical grants, the National Institutes of Health and the Department of Veterans Affairs.

Publications:
Hussain, A., DiPaola, R., Baron, A., Higano, C., Tchekmedyian, S., Miller, J.A., Rothermel, J. A phase IIa trial of weekly EPO906 in patients with hormone refractory prostate cancer. Proc. of the American Society of Clinical Oncology, June 2004.

Picus, J., Halabi, S., Small, E., Hussain, A., Phillips, G., Kaplan, E., Vogelzang, N. Efficacy of peripheral androgen blockade on prostate cancer: results of CALGB 9782. Proc. of the American Society of Clinical Oncology, June 2004.

Mannuel, H., Dawson, N., Engstrom, C., Dorsey, B., Besche, M., Smooth, J., Guo, C., Hussain, A. Phase I/II trial of weekly doxorubicin/docetaxel followed by hormone ablation in recurrent prostate cancer. Proc. of the American Society of Clinical Oncology, June 2004.

DiBiase, S., Dawson, N., Naslund, M., Hussain, A., Kataria, R., Bangalore, M., Dhople, A., Guo, C., Amin, P. Phase II study of combined external beam radiation therapy, brachytherapy, total androgen suppression, and adjuvant docetaxel in poor-risk, localized prostate cancer. Proc. of the American Society of Clinical Oncology, June 2004.

Tang, Y., Khan, M., Hussain, A. Evaluation of chemohormone therapy in a SCID mouse model of human prostate cancer. AACR Special Conference in Cancer Research: Basic, Translational, and Clinical Advances in Prostate Cancer, A32, November 17-21, 2004.

Mannuel, H., Dawson, N., Khan, I., Feldman, M., Boyle, L., Besche, M., Smoot, J., Engstrom, G., Monroe, M., Hussain, A. Initial results of ongoing phase I/II studies of weekly doxorubicin/docetaxel in men with hormone refractory and hormone sensitive prostate cancer. Proc. of the American Society of Clinical Oncology, May 2005.

Hussain, A., Tang, Y., Khan, M., Goloubeva, O. Docetaxel followed by castration improves anti-tumor effects in human prostate cancer cell-bearing SCID mice. Proc. of the American Society of Clinical Oncology, May 2005.

Hudes, G., Celano, P., Torti, F., Tabatabai, A., Murgo, A., Hussain, A. Phase II study of weekly paclitaxel and bryostatin-1 in hormone refractory prostate cancer. Proc. of the American Society of Clinical Oncology, May 2005.

Smith, M., Kabbinavar, F., Saad, F., Hussain, A., Hei, Y-J., Small, E., Cook, R., Higano, C. Natural history of rising serum PSA in men with castrate non metastatic prostate cancer. Proc. of the American Society of Clinical Oncology, May 2005.

Tang, Y., Geng, Z., Goloubeva, O., Wang, L., Hussain, A. Angiogenesis in LNCaP xenografts undergoing hormone ablation. AACR Special Conference in Cancer Research: Anti-angiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back, A38, November 9-13, 2005.

Tang, Y., Khan, M.A., Goloubeva, O., Lee, D.I., Jelovac, D., Brodie, A.M., and Hussain, A. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing SCID mice. Clin. Cancer Res, 12(1): 169-174, 2006.

O'Neill, J., Velalar, C.N., Lee, D.I., Zhang, B., Nakanishi, T., Tang, Y., Selaru, F., Ross, D., Meltzer, S.J., and Hussain, A. Thapsigargin resistance in human prostate cancer cells. Cancer, 107(3): 649-659, 2006.

Lee, D.I., Sumbilla, C., Lee, M., Velalar, C.N., Klein, M.G., Ross, D.D., Inesi, G., and Hussain, A. Mechanisms of resistance and adaptation to thapsigargin in PC3 and DU145 prostate cancer cells. Arch. Biochem. Biophys., 464: 19-27, 2007.

Tang, Y., Wang, L., Goloubeva, O., Khan, M.A., Zhang, B., and Hussain, A. Divergent effects of castration on prostate tumors in transgenic adenocarcinoma of mouse prostate mice: possible implications for therapy. Clin Cancer Res, 14:2936-43, 2008.

Zafar, S., Hussain, A., Liu, D., Lewis, D., and Inesi, G., Specificity of ligand binding to transport sites: Ca2+ binding to the Ca2+ transport ATPase and its dependence on H+ and Mg2+. Arch. Biochem. Biophys (In press)

Hussain, A., DiPaolo, R., Baron, A., Higano, C., Tchekmedyian, N., Johri, A., Phase II trial of patupilone in castration resistant prostate cancer. Annals Onc (Accepted).